PNC Managed Account Solutions’s Anika Therapeutics ANIK Stock Holding History

PNC Managed Account Solutions’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$11K	Buy	+249	New	+$10.6K	﹤0.01%	452

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PNC Managed Account Solutions's ANIK Position: Q2 2021 in Review

PNC Managed Account Solutions opened a new position in Anika Therapeutics (ANIK) in Q2 2021: 249 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #452 among its holdings.

139 funds tracked by Wall St. Rank hold ANIK as of Q2 2021.

PNC Managed Account Solutions held 249 shares of Anika Therapeutics worth $11K as of Q2 2021.
Anika Therapeutics was a new PNC Managed Account Solutions position in Q2 2021.
Anika Therapeutics made up ﹤0.01% of PNC Managed Account Solutions's portfolio in Q2 2021, its #452 holding.
139 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2021.

Based on PNC Managed Account Solutions's 13F filing for Q2 2021, filed 6 Aug 2021.